Grant Search

Cancer Type

Keyword Search  

Categories

Grant Amount
>=

<=





Results: 51

OLIG2 Targeting in DIPG using the novel small molecular inhibitor ...

Diffuse Intrinsic Pontine Glioma (DIPG) is an incurable brain stem glioma predominantly arising in young children, better options to treat this aggressive disease are urgently needed. Oligodendrocyte transcription factor 2 (OLIG2) is mostly expressed in restricted domains of the brain and spinal cord ventricular zone which give rise to oligodendrocytes and ...

INNOVATIVE MODELS OF THE BRAIN MICROENVIRONMENT TO IDENTIFY NEW TREATMENTS ...

Brain tumours are the leading cause of disease related mortality in children, with medulloblastoma (MB) representing the most common malignant paediatric brain tumour. The outcome for high-risk patients however remains poor and survivors frequently relapse. We have developed a novel computational approach to identify networks of signalling proteins that drive ...

Modulation of intra-tumor hypoxia to sensitize DIPG irradiation and initiate ...

Malignant gliomas in specific region like brain pons are not curable as they cannot be surgically resected and are only transiently benefiting from local irradiation and in some cases from targeted therapies. These aggressive brain tumors are molecularly well known as they are characterized by a driver mutation. This abnormality ...

Targeting hypoxia and mitochondrial metabolism with repurposing drugs as an ...

Abstract Diffuse intrinsic pontine glioma (DIPG) is a rare and incurable brain tumor that arises in the brainstem of children predominantly between the ages of 6 and 9.  Unlike many brain tumors, DIPGs cannot be removed through surgery due to its sensitive location. The standard of care today remains radiation therapy (...

Precision Therapy to Overcome Chemoresistance in Pediatric Glioblastoma

Glioblastoma (GBM) remains one of the most aggressive and lethal forms of cancer. Despite the best available treatment options including surgical resection, radiotherapy, and chemotherapy, prognosis is poor in glioblastoma, with a median overall survival of 14 months.1Currently, temozolomide (TMZ) is the preferred chemotherapeutic drug in the treatment of GBM ...